Summary

“Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on Partnerships, Licensing Agreements, M&As, Equity/Debt Offerings, Private Equity and Venture Financing transactions registered in the pharmaceutical and healthcare industry in 2012. The report presents detailed comparative data on the number of deals and their value in the past five years categorized into deal types, segments, and geographies. Additionally, the report provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.
Data presented in this report is derived from Our proprietary in-house deals database and primary and secondary research.




Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and womens health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the last five years.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.





Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.





Browse complete Report on:
http://www.aarkstore.com/pharmaceuticals-healthcare/109488/pharmaceutical-healthcare-annual-deals-analysis-ma-and-investments-trends-2012





Table of Content

1.1 List of Tables
1.2 List of Figures
2 Pharmaceutical & Healthcare, Global, Deals Summary
2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2012
2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2012 by Quarter
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2012
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2012
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2012
2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2012
2.5.1 Abbott Completes Private Placement of Notes for $14.7 Billion
2.5.2 Nestle Completes Acquisition of Pfizer Nutrition from Pfizer for $11.85 Billion
2.5.3 Roche Revises Offer Price to Acquire Illumina for Up To $8.2 Billion
2.5.4 Aetna Receives Shareholders Approval to Acquire Coventry Health Care for $7.3 Billion
2.5.5 Walgreen Acquires 45% Stake in Alliance Boots from KKR And AXA Private Equity for $6.7 Billion
2.5.6 Watson Pharma Completes Acquisition of Actavis Group for $5.92 Billion
2.5.7 Bristol-Myers Squibb Completes Acquisition of Amylin Pharma for $5.3 Billion
2.5.8 GlaxoSmithKline Completes Public Offering of Notes for $5 Billion
2.5.9 UnitedHealth Completes Acquisition of 60% Stake in Amil Participacoes
2.5.10 WellPoint Completes Acquisition of Amerigroup for $4.9 Billion





Related Reports:

http://www.aarkstore.com/pharmaceuticals-healthcare/112168/essential-thrombocythemia-pipeline-review-h1-2015

http://www.aarkstore.com/pharmaceuticals-healthcare/112167/oligodendroglioma-pipeline-review-h1-2015

http://www.aarkstore.com/pharmaceuticals-healthcare/112166/inclusion-body-myositis-pipeline-review-h1-2015

http://www.aarkstore.com/pharmaceuticals-healthcare/112165/proliferative-diabetic-retinopathy-pipeline-review-h1-2015




About Aarkstore Enterprise

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.



Contact Details:

Aarkstore Enterprise
Phone: +91 998 729 5242
Email: [email protected]
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/